Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
J. Clin. Oncol 2021 May 28;[EPub Ahead of Print], JA Pollard, E Guest, TA Alonzo, RB Gerbing, MR Loken, LE Brodersen, EA Kolb, R Aplenc, S Meshinchi, SC Raimondi, B Hirsch, AS GamisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.